Evaluation of elabela, visfatin, and chemerin levels as inflammation biomarkers in COVID-19
Yükleniyor...
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
OBJECTIVE: The aim of this
study was to investigate if inflammation biomarkers elabela, visfatin, and chemerin will be useful
in the diagnosis of patients with COVID-19.
PATIENTS AND METHODS: This prospective case-control study included 33 patients with
COVID-19 and 30 healthy matched controls. 33 patients, aged 18 years and older, diagnosed with
COVID-19 and followed up for one month were included in the study. Blood samples were taken
from the patients on the first day they were diagnosed with COVID-19, and levels of elabela (ELA),
visfatin, chemerin, white blood cells (WBC), C-reactive protein (CRP) and procalcitonin (PCT) were
assessed. Blood samples were also taken from 30
healthy volunteers for the control group. The ELA,
visfatin and chemerin levels measured in the patients on day one were compared with those measured in the control group and with the WBC, CRP
and PCT levels measured in the patients.
RESULTS: Visfatin levels measured in COVID-19
patients were significantly higher than in the
healthy control group. There was no significant
difference in ELA and chemerin levels between
the two groups. A significant positive correlation
was found between chemerin and visfatin levels
in the patients. A significant negative correlation
was found between the levels of ELA-chemerin
and ELA-visfatin in the patients. There was no significant correlation between elabela, visfatin and
chemerin levels and WBC, CRP, PCT levels.
CONCLUSIONS: Measurement of visfatin levels
may be helpful in patients with COVID-19. However,
two other biomarkers in our study, ELA and chemerin, were found not to be useful in diagnosing
COVID-19. New inflammatory biomarkers may help
to diagnose a disease in which the inflammatory response is at the forefront, such as COVID-19.
New studies are needed on this subject.
Açıklama
Anahtar Kelimeler
COVID-19, Elabela, Visfatin, Chemerin
Kaynak
European Review for Medical and Pharmacological Sciences
WoS Q Değeri
N/A
Scopus Q Değeri
Q2
Cilt
27
Sayı
22
Künye
Mermutluoğlu, Ç. ve Tekin, R. (2023). Evaluation of elabela, visfatin, and chemerin levels as inflammation biomarkers in COVID-19. European Review for Medical and Pharmacological Sciences, 27(22), 11180-11184.
